{"id":"bopv-1-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Vaccine-derived poliovirus (VDPV) shedding"},{"rate":null,"effect":"Mild gastrointestinal symptoms"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers live attenuated (weakened) poliovirus serotypes 1 and 3 orally, stimulating both intestinal mucosal immunity (IgA) and systemic humoral immunity (IgG) against these poliovirus types. This approach provides protection against wild-type poliovirus infection while minimizing the risk associated with monovalent formulations by covering two serotypes simultaneously.","oneSentence":"bOPV 1,3 is a bivalent oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:17.710Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Poliomyelitis prevention in infants and children"}]},"trialDetails":[{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03581734","phase":"PHASE3","title":"Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-01","conditions":"Vaccine Reaction","enrollment":579},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT03722004","phase":"PHASE4","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2018-12-18","conditions":"Poliomyelitis","enrollment":1256},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT02434770","phase":"PHASE3","title":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":750},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT02766816","phase":"PHASE3","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","status":"COMPLETED","sponsor":"Bilthoven Biologicals","startDate":"2016-06-08","conditions":"Immune Response to Oral Polio Vaccine","enrollment":1120},{"nctId":"NCT03821441","phase":"PHASE3","title":"Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-01-04","conditions":"Poliomyelitis","enrollment":1165},{"nctId":"NCT02785705","phase":"PHASE3","title":"Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":600},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01586572","phase":"NA","title":"Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-04","conditions":"Polio","enrollment":1000},{"nctId":"NCT01841671","phase":"PHASE4","title":"Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine","status":"UNKNOWN","sponsor":"University of Chile","startDate":"2013-04","conditions":"Polio","enrollment":570},{"nctId":"NCT01813604","phase":"PHASE3","title":"Immunogenicity of Inactivated and Live Polio Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-11","conditions":"Poliomyelitis","enrollment":1206},{"nctId":"NCT01633216","phase":"PHASE4","title":"Poliovirus Vaccine Trial in Bangladesh","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2012-05","conditions":"Healthy Infants","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bivalent Oral Polio Vaccine"],"phase":"marketed","status":"active","brandName":"bOPV 1,3","genericName":"bOPV 1,3","companyName":"Institute of Medical Biology, Chinese Academy of Medical Sciences","companyId":"institute-of-medical-biology-chinese-academy-of-medical-sciences","modality":"Biologic","firstApprovalDate":"","aiSummary":"bOPV 1,3 is a bivalent oral polio vaccine containing live attenuated poliovirus types 1 and 3 that induces mucosal and systemic immunity against poliomyelitis. Used for Poliomyelitis prevention in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}